Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of June 10, 2025 • 11:31 PM ET

Date/Time Source News Release
06/05/2025 08:00 AM EDT GlobeNewswire Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107)
06/04/2025 08:45 AM EDT GlobeNewswire Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)
05/14/2025 07:30 AM EDT GlobeNewswire Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update
05/12/2025 08:40 AM EDT GlobeNewswire Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial
05/07/2025 09:00 AM EDT GlobeNewswire Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast
05/06/2025 09:00 AM EDT GlobeNewswire Moleculin Announces World Health Organization Approval of "naxtarubicin" as International Non-Proprietary Name for Annamycin
05/05/2025 08:45 AM EDT GlobeNewswire Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents
04/29/2025 08:35 AM EDT GlobeNewswire Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer
04/17/2025 08:30 AM EDT GlobeNewswire Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025
04/01/2025 08:30 AM EDT GlobeNewswire Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial
Page

Additional News

As of June 10, 2025 • 11:31 PM ET

Date/Time Source News Release
06/02/2025 05:24 PM EDT SeekingAlpha Moleculin Biotech files to sell 10.99M shares of common stock, warrants
05/14/2025 12:20 PM EDT SeekingAlpha Moleculin signals first 45-patient unblinding for Phase 3 AML trial by end of 2025 as key regulatory milestones achieved
05/14/2025 12:20 PM EDT SeekingAlpha Moleculin Biotech, Inc. (MBRX) Q1 2025 Earnings Call Transcript
05/14/2025 07:53 AM EDT SeekingAlpha Moleculin Biotech GAAP EPS of -$0.69
05/13/2025 10:00 AM EDT SeekingAlpha Here are the major earnings after the close today
05/13/2025 07:00 AM EDT US Earnings Reports Expected US Company Earnings on Tuesday, May 13th, 2025
05/13/2025 05:30 AM EDT US Earnings Reports Expected earnings - Moleculin Biotech Inc.
05/12/2025 04:21 PM EDT PRISM News Moleculin Gains EU Clearance to Expand Leukemia Drug Trial Across Nine EU Countries
04/01/2025 09:55 AM EDT Zacks Here's Why Moleculin Biotech (MBRX) Is a Great 'Buy the Bottom' Stock Now
03/31/2025 05:09 PM EDT SeekingAlpha Moleculin Biotech files to sell 18.2M shares of common stock for holders
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.